<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000489115"><TermName>Tykerb</TermName><TermPronunciation>(TY-kerb)</TermPronunciation><TermDefinition><DefinitionText>A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Tykerb is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor. Also called GW572016, lapatinib,  and lapatinib ditosylate.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000733018" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Tykerb&quot;" language="en" id="_3"/><MediaLink ref="CDR0000733017" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Tykerb&quot;" language="es" id="_4"/><SpanishTermName>Tykerb</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa junto con otro medicamento anticanceroso para tratar el cáncer de mama que es positivo al HER2 y que ha avanzado o se ha metastatizado (diseminado hasta otras partes del cuerpo) después de haber sido tratado con otros medicamentos. Tykerb también está en estudio para el tratamiento de otros tipos de cáncer. Es un tipo de inhibidor dual de la tirosina cinasa de ErbB-2 y RFCE. También se llama ditosilato de lapatinib, GW572016,  y lapatinib.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-06-02</DateFirstPublished><DateLastModified>2007-03-15</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000539385">Lapatinib Ditosylate</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
